| Source: |
| Type: |
| Tumor cell cycle arrest refers to the process by which cancer cells stop progressing through the cell cycle, which is the series of phases that a cell goes through to divide and replicate. This arrest can occur at various checkpoints in the cell cycle, including the G1, S, G2, and M phases.
S, G1, G2, and M are the four phases of mitosis. |
| 6308- | Cro, | Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage |
| - | vitro+vivo, | PC, | Bxpc-3 |
| 6305- | Cro, | Bridging Preclinical and Clinical Evidence on Crocin in Breast Cancer |
| - | Review, | BC, | NA |
| 6334- | Cro, | Eug, | Rad, | Crocin and eugenol enhance radiosensitivity in oral squamous cell carcinoma cells via apoptotic pathways and cell cycle regulation. Type of study: in vitro |
| - | in-vitro, | OS, | NA |
| 6294- | Cro, | Crocetin and Crocin from Saffron in Cancer Chemotherapy and Chemoprevention |
| - | Review, | Var, | NA |
| 6292- | Cro, | Crocetin induces cytotoxicity and enhances vincristine-induced cancer cell death via p53-dependent and -independent mechanisms |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | A549 | - | in-vitro, | Ovarian, | SKOV3 |
| 6521- | CRV, | L-carvone induces p53, caspase 3 mediated apoptosis and inhibits the migration of breast cancer cell lines |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 6520- | CRV, | Health Benefits and Pharmacological Properties of Carvone |
| - | Review, | Nor, | NA |
| 6523- | CRV, | Anticancer effects of Carvone in myeloma cells is mediated through the inhibition of p38 MAPK signalling pathway, apoptosis induction and inhibition of cell invasion |
| - | NA, | Melanoma, | NA |
| 6528- | CRV, | D-carvone inhibits growth, migration, cell cycle at G0/G1 phase and induces apoptosis in A431 cells by disrupting mitochondrial membrane potential |
| - | in-vitro, | Melanoma, | A431 |
| 6530- | CRV, | Monoterpenes as Anticancer Therapeutic Agents |
| - | Review, | Var, | NA |
| 1602- | Cu, | A simultaneously GSH-depleted bimetallic Cu(ii) complex for enhanced chemodynamic cancer therapy† |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | 4T1 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Liver, | HepG2 |
| 6196- | Cuc, | Cucurbitacins – A Promising Target for Cancer Therapy |
| - | Review, | Var, | NA |
| 6188- | Cuc, | Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation |
| 6189- | Cuc, | Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 6190- | Cuc, | Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells |
| - | in-vitro, | Colon, | SW480 |
| 6191- | Cuc, | Growth inhibitory effect of Cucurbitacin E on breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 6192- | Cuc, | Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway |
| - | vitro+vivo, | CRC, | NA |
| 6195- | Cuc, | Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends |
| - | Review, | Var, | NA |
| 6185- | Cuc, | Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | AD, | NA |
| 6184- | Cuc, | Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells |
| - | vitro+vivo, | PC, | NA |
| 6197- | Cuc, | Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SH‑SY5Y human neuroblastoma cells |
| - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 6199- | Cuc, | Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 6201- | Cuc, | Cucurbitacin B and Its Derivatives: A Review of Progress in Biological Activities |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6227- | CUR, | Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations |
| - | Review, | Var, | NA |
| 6214- | CUR, | Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve |
| 6231- | CUR, | Curcumin induces apoptosis in human hepatocellular carcinoma cells by decreasing the expression of STAT3/VEGF/HIF-1α signaling |
| - | in-vitro, | Liver, | HepG2 |
| 6223- | CUR, | Curcumin Rewires the Tumor Metabolic Landscape: Mechanisms and Clinical Prospects |
| - | Review, | Var, | NA |
| 6221- | CUR, | Oxidative Stress and Cancer: Harnessing the Therapeutic Potential of Curcumin and Analogues Against Cancer |
| - | Review, | Var, | NA |
| 6720- | CUR, | SFN, | DHCA, | Synergistic Combinations of Curcumin, Sulforaphane, and Dihydrocaffeic Acid against Human Colon Cancer Cells |
| - | in-vitro, | Colon, | HT29 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Nor, | FHC |
| 2654- | CUR, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 4652- | CUR, | Anticancer effect of curcumin on breast cancer and stem cells |
| - | Review, | BC, | NA |
| 4671- | CUR, | Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy |
| - | in-vitro, | CRC, | NA |
| 4675- | CUR, | Curcumin improves the efficacy of cisplatin by targeting cancer stem-like cells through p21 and cyclin D1-mediated tumour cell inhibition in non-small cell lung cancer cell lines |
| - | in-vitro, | NSCLC, | A549 |
| 1411- | CUR, | Cisplatin, | Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects |
| - | Review, | Var, | NA |
| 1409- | CUR, | Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma |
| - | in-vivo, | CCA, | Walker256 |
| 1505- | CUR, | Epigenetic targets of bioactive dietary components for cancer prevention and therapy |
| - | Review, | NA, | NA |
| 474- | CUR, | Modification of radiosensitivity by Curcumin in human pancreatic cancer cell lines |
| - | in-vitro, | PC, | PANC1 | - | in-vitro, | PC, | MIA PaCa-2 |
| 468- | CUR, | 5-FU, | Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability |
| - | vitro+vivo, | Liver, | HepG2 | - | vitro+vivo, | Liver, | 402 | - | vitro+vivo, | Liver, | Bel7 |
| 479- | CUR, | Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments |
| - | in-vitro, | Tong, | CAL27 |
| 459- | CUR, | Curcumin inhibits cell proliferation and motility via suppression of TROP2 in bladder cancer cells |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | in-vitro, | Bladder, | RT4 |
| 477- | CUR, | Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells |
| - | in-vitro, | Cerv, | SiHa |
| 480- | CUR, | Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells |
| - | in-vitro, | GBM, | SNB19 |
| 437- | CUR, | Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids |
| - | vitro+vivo, | CRC, | TCO1 | - | vitro+vivo, | CRC, | TCO2 |
| 456- | CUR, | Curcumin Promoted miR-34a Expression and Suppressed Proliferation of Gastric Cancer Cells |
| - | vitro+vivo, | GC, | SGC-7901 |
| 455- | CUR, | Curcumin Affects Gastric Cancer Cell Migration, Invasion and Cytoskeletal Remodeling Through Gli1-β-Catenin |
| - | in-vitro, | GC, | SGC-7901 |
| 453- | CUR, | Cellular uptake and apoptotic properties of gemini curcumin in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 452- | CUR, | Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells |
| - | vitro+vivo, | HNSCC, | SCC9 | - | vitro+vivo, | HNSCC, | FaDu | - | vitro+vivo, | HNSCC, | HaCaT |
| 448- | CUR, | Heat shock protein 27 influences the anti-cancer effect of curcumin in colon cancer cells through ROS production and autophagy activation |
| - | in-vitro, | CRC, | HT-29 |
| 442- | CUR, | 5-FU, | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress |
| - | in-vitro, | CRC, | HCT116 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:322 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid